Literature DB >> 24220909

Plasma alkylresorcinol metabolites as biomarkers for whole-grain intake and their association with prostate cancer: a Swedish nested case-control study.

Isabel Drake1, Emily Sonestedt, Bo Gullberg, Anders Bjartell, Håkan Olsson, Herman Adlercreutz, Matti J Tikkanen, Elisabet Wirfält, Peter Wallström.   

Abstract

BACKGROUND: Observational studies have mostly found no association between self-reported whole-grain intake and prostate cancer. Plasma alkylresorcinol metabolites have been suggested as biomarkers for whole-grain intake in free-living populations.
METHODS: We investigated the major dietary and lifestyle determinants of plasma alkylresorcinol metabolites in a nested case-control study (1,016 cases and 1,817 controls) in the Malmö Diet and Cancer Study. Multivariate adjusted ORs and 95% confidence intervals (95% CI) were estimated to assess the association between plasma alkylresorcinol metabolites and prostate cancer using logistic regression.
RESULTS: Whole-grain intake, waist circumference, educational level, and smoking status were the main determinants of alkylresorcinol metabolites. We observed significant correlations between alkylresorcinol metabolites and whole-grain (r = 0.31) and fiber (r = 0.27) intake. Metabolite concentration was positively associated with prostate cancer risk (Poverall effect = 0.0004) but the association was not linear (P = 0.04). The lowest risk was seen among men with moderate plasma concentrations. The OR for high compared with moderate plasma alkylresorcinol metabolites was 1.41 (95% CI, 1.10-1.80) for prostate cancer.
CONCLUSIONS: Results suggest that plasma alkylresorcinol metabolites are mainly determined by whole-grain intake in this nested case-control study of Swedish men. The increased risk of prostate cancer seen among men with high plasma alkylresorcinol metabolites requires further study, but residual confounding, detection bias, or competing risks of nonprostate cancer-related deaths are plausible explanations that could not be ruled out. IMPACT: We found no evidence of a protective effect of whole grains on incident prostate cancer. Further validation of alkylresorcinol metabolites as a biomarker for whole-grain intake is needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24220909     DOI: 10.1158/1055-9965.EPI-13-0878

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

1.  Comparison of plasma alkylresorcinols (AR) and urinary AR metabolites as biomarkers of compliance in a short-term, whole-grain intervention study.

Authors:  Nicola M McKeown; Matti Marklund; Jiantao Ma; Alastair B Ross; Alice H Lichtenstein; Kara A Livingston; Paul F Jacques; Helen M Rasmussen; Jeffrey B Blumberg; C-Y Oliver Chen
Journal:  Eur J Nutr       Date:  2015-06-05       Impact factor: 5.614

2.  DHPPA, a major plasma alkylresorcinol metabolite reflecting whole-grain wheat and rye intake, and risk of metabolic syndrome: a case-control study.

Authors:  Li Zhou; Shan Hu; Shuang Rong; Xiaoxing Mo; Qiang Wang; Jiawei Yin; Xiaobo Peng; Xiaoqin Li; Liangkai Chen; Zhilei Shan; Guohong Liu; Taoping Sun; Liegang Liu
Journal:  Eur J Nutr       Date:  2022-04-22       Impact factor: 4.865

Review 3.  Biomarkers of cereal food intake.

Authors:  Rikard Landberg; Kati Hanhineva; Kieran Tuohy; Mar Garcia-Aloy; Izabela Biskup; Rafael Llorach; Xiaofei Yin; Lorraine Brennan; Marjukka Kolehmainen
Journal:  Genes Nutr       Date:  2019-10-12       Impact factor: 5.523

4.  Biomarkers of Whole-Grain and Cereal-Fiber Intake in Human Studies: A Systematic Review of the Available Evidence and Perspectives.

Authors:  Mohamad Jawhara; Signe Bek Sørensen; Berit Lilienthal Heitmann; Vibeke Andersen
Journal:  Nutrients       Date:  2019-12-06       Impact factor: 5.717

Review 5.  An Overview of Alkylresorcinols Biological Properties and Effects.

Authors:  Anastasia A Zabolotneva; Olga P Shatova; Anastasia A Sadova; Aleksandr V Shestopalov; Sergei A Roumiantsev
Journal:  J Nutr Metab       Date:  2022-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.